Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022010043 - TRICYCLIC DILACTONE COMPOUND, AND PRODUCTION METHOD AND USE THEREOF

Publication Number WO/2022/010043
Publication Date 13.01.2022
International Application No. PCT/KR2020/014554
International Filing Date 23.10.2020
IPC
C07D 493/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
493Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C12N 1/20 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
C12P 17/18 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
17Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms
18containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
A61K 31/366 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
366having six-membered rings, e.g. delta-lactones
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A23L 33/10 2016.1
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
CPC
A23L 33/10
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT
33Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
10using additives
A23V 2002/00
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
2002Food compositions, function of food ingredients or processes for food or foodstuffs
A23V 2200/322
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
2200Function of food ingredients
30Foods, ingredients or supplements having a functional effect on health
322having an effect on the health of the nervous system or on mental function
A23V 2250/30
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
2250Food ingredients
30Other Organic compounds
A61K 31/366
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
366having six-membered rings, e.g. delta-lactones
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants
  • 서울대학교산학협력단 SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION [KR]/[KR]
  • 연세대학교 산학협력단 INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY [KR]/[KR]
Inventors
  • 오동찬 OH, Dong-Chan
  • 김병용 KIM, Byung-Yong
  • 신종헌 SHIN, Jongheon
  • 김영수 KIM, Youngsoo
  • 권윤 KWON, Yun
  • 신지수 SHIN, Jisu
Agents
  • 리앤목 특허법인 Y.P.LEE, MOCK & PARTNERS
Priority Data
10-2020-008312106.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) TRICYCLIC DILACTONE COMPOUND, AND PRODUCTION METHOD AND USE THEREOF
(FR) COMPOSÉ DILACTONE TRICYCLIQUE, PROCÉDÉ DE PRÉPARATION ET UTILISATION ASSOCIÉS
(KO) 삼중환 다이락톤 화합물, 이의 생산 방법, 및 용도
Abstract
(EN) A novel tricyclic dilactone compound, a strain producing same, a method for producing same, and a use thereof are provided. The tricyclic dilactone compound inhibits aggregation of amyloid-beta and tau proteins, inhibits apoptosis, has anti-inflammatory activity, and can be used to prevent, treat, or alleviate various degenerative brain diseases and cognitive disorders including Alzheimer's disease.
(FR) L'invention concerne un nouveau composé dilactone tricyclique, une souche le produisant, son procédé de production et son utilisation. Le composé dilactone tricyclique inhibe l'agrégation des protéines amyloïdes bêta et tau, inhibe l'apoptose, a une activité anti-inflammatoire, et peut être utilisé pour prévenir, traiter ou soulager diverses maladies cérébrales dégénératives et des troubles cognitifs comprenant la maladie d'Alzheimer.
(KO) 신규한 삼중환 다이락톤 화합물, 이를 생산하는 균주, 이를 생산하는 방법, 및 이의 용도를 제공한다. 상기 삼중환 다이락톤 화합물은 아밀로이드-베타와 타우 단백질의 응집을 억제하고, 세포사멸 억제, 및 항염 활성을 갖고, 알츠하이머병을 포함한 다양한 퇴행성 뇌질환 및 인지 장애를 예방, 치료, 또는 개선하는데 사용할 수 있다.
Related patent documents
Latest bibliographic data on file with the International Bureau